{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T12:32:08Z","timestamp":1777379528602,"version":"3.51.4"},"reference-count":56,"publisher":"SAGE Publications","issue":"8","license":[{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["AIDS Research and Human Retroviruses"],"published-print":{"date-parts":[[2019,8]]},"abstract":"<jats:p>\n                    Significant progress has been made in the diagnostics and treatment of AIDS since the discovery of the human immunodeficiency virus type 1 (HIV-1) in 1983. The remarkable effectiveness of combined antiretroviral therapy (cART) is evidenced by mortality reduction, control of peripheral blood viral load, and in a nearly normal quality of HIV patients' lives. Remaining obstacles in treatment and cure are drug toxicities and side effects, viral resistance, persistence of HIV-1 reservoirs on termination of cART treatment, the cost of lifelong antiretroviral therapy, and the stigma associated with taking antiretroviral drugs. As determined by plasma viral RNA and peripheral blood mononuclear cells (PBMC) proviral DNA, we show improved suppression of productive HIV infection in human CD34\n                    <jats:sup>+<\/jats:sup>\n                    hematopoietic stem cell-engrafted NOD (nonobese diabetic)-SCID (severe combined immunodeficiency)-il2rg\n                    <jats:sup>\u2212\/\u2212<\/jats:sup>\n                    (NSG) mice by combined treatment with cART and CCR5 targeting drugs, compared with cART alone, as well as an increased preservation of human CD4\n                    <jats:sup>+<\/jats:sup>\n                    T cells (defined as CD45\n                    <jats:sup>+<\/jats:sup>\n                    CD3\n                    <jats:sup>+<\/jats:sup>\n                    CD4\n                    <jats:sup>+<\/jats:sup>\n                    cells) and CD4\n                    <jats:sup>+<\/jats:sup>\n                    \/CD8\n                    <jats:sup>+<\/jats:sup>\n                    cell ratios in infected mice. The data also suggest a possible reduction in viral reservoirs. Our data confirm that this animal model is suitable for detection of productive HIV infection, replication, and establishment of viral reservoirs. The data also provide proof of principle for the utility of combining CCR5 targeting drugs, maraviroc and rapamycin, with traditional cART to improve control of viremia and reduce viral reservoirs. This study thus serves as a model for future HIV-1 studies that could lead to the clinical development of new generations of antiretroviral drugs.\n                  <\/jats:p>","DOI":"10.1089\/aid.2018.0305","type":"journal-article","created":{"date-parts":[[2019,5,17]],"date-time":"2019-05-17T05:14:54Z","timestamp":1558070094000},"page":"718-728","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":7,"title":["Suppression of Active HIV-1 Infection in CD34\n                    <sup>+<\/sup>\n                    Hematopoietic Humanized NSG Mice by a Combination of Combined Antiretroviral Therapy and CCR5 Targeting Drugs"],"prefix":"10.1177","volume":"35","author":[{"given":"Olga S.","family":"Latinovic","sequence":"first","affiliation":[{"name":"Institute of Human Virology, University of Maryland School of Medicine, Baltimore, Maryland."},{"name":"Department of Microbiology and Immunology, University of Maryland School of Medicine, Baltimore, Maryland."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lauren M.","family":"Neal","sequence":"additional","affiliation":[{"name":"Institute of Human Virology, University of Maryland School of Medicine, Baltimore, Maryland."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yutaka","family":"Tagaya","sequence":"additional","affiliation":[{"name":"Institute of Human Virology, University of Maryland School of Medicine, Baltimore, Maryland."},{"name":"School of Medicine, University of Maryland School of Medicine, Baltimore, Maryland."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alonso","family":"Heredia","sequence":"additional","affiliation":[{"name":"Institute of Human Virology, University of Maryland School of Medicine, Baltimore, Maryland."},{"name":"School of Medicine, University of Maryland School of Medicine, Baltimore, Maryland."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandra","family":"Medina-Moreno","sequence":"additional","affiliation":[{"name":"Institute of Human Virology, University of Maryland School of Medicine, Baltimore, Maryland."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan C.","family":"Zapata","sequence":"additional","affiliation":[{"name":"Institute of Human Virology, University of Maryland School of Medicine, Baltimore, Maryland."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marvin","family":"Reitz","sequence":"additional","affiliation":[{"name":"Institute of Human Virology, University of Maryland School of Medicine, Baltimore, Maryland."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph","family":"Bryant","sequence":"additional","affiliation":[{"name":"Institute of Human Virology, University of Maryland School of Medicine, Baltimore, Maryland."},{"name":"Department of Pathology, University of Maryland School of Medicine, Baltimore, Maryland."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert R.","family":"Redfield","sequence":"additional","affiliation":[{"name":"Institute of Human Virology, University of Maryland School of Medicine, Baltimore, Maryland."},{"name":"School of Medicine, University of Maryland School of Medicine, Baltimore, Maryland."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2019,8]]},"reference":[{"key":"e_1_3_4_2_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0148231"},{"key":"e_1_3_4_3_2","doi-asserted-by":"publisher","DOI":"10.1021\/acs.molpharmaceut.5b00544"},{"key":"e_1_3_4_4_2","doi-asserted-by":"publisher","DOI":"10.1080\/15321819.2014.969436"},{"key":"e_1_3_4_5_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1315295110"},{"key":"e_1_3_4_6_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.01617-15"},{"key":"e_1_3_4_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2055-6640(20)30490-8"},{"key":"e_1_3_4_8_2","doi-asserted-by":"publisher","DOI":"10.1038\/nm880"},{"key":"e_1_3_4_9_2","doi-asserted-by":"publisher","DOI":"10.1038\/487439a"},{"key":"e_1_3_4_10_2","doi-asserted-by":"publisher","DOI":"10.1038\/nature16933"},{"key":"e_1_3_4_11_2","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000000066"},{"key":"e_1_3_4_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.virol.2013.02.028"},{"key":"e_1_3_4_13_2","doi-asserted-by":"publisher","DOI":"10.3851\/IMP1917"},{"key":"e_1_3_4_14_2","first-page":"45","article-title":"Size, Composition, and evolution of HIV DNA populations during early antiretroviral therapy and intensification with Maraviroc","volume":"45","author":"Chaillon A","year":"2017","unstructured":"Chaillon A, , Gianella S, , Lada SM, et al.: Size, Composition, and evolution of HIV DNA populations during early antiretroviral therapy and intensification with Maraviroc. J Virol, 2017; 45:45\u201356.","journal-title":"J Virol"},{"key":"e_1_3_4_15_2","volume-title":"Nat Med","author":"Buzon MJ","year":"2010","unstructured":"Buzon MJ, , Massanella M, , Libre JM, et al.: HIV-1 replication and immune dynamics are affected by raltegravir intensification of HAART-suppressed subjects. Nat Med, 2010;16:."},{"key":"e_1_3_4_16_2","doi-asserted-by":"publisher","DOI":"10.3390\/v10040157"},{"key":"e_1_3_4_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2017.10.023"},{"key":"e_1_3_4_18_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrmicro3352"},{"key":"e_1_3_4_19_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.01389-16"},{"key":"e_1_3_4_20_2","first-page":"823","article-title":"Envelope-specific antibodies and antibody-derived molecules for treating and curing HIV infection","volume":"15","author":"Ferrari G","year":"2016","unstructured":"Ferrari G, , Haynes BF, , Koenig S, et al.: Envelope-specific antibodies and antibody-derived molecules for treating and curing HIV infection. Nat Rev, 2016; 15:823\u2013834.","journal-title":"Nat Rev"},{"key":"e_1_3_4_21_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.gt.3302923"},{"key":"e_1_3_4_22_2","doi-asserted-by":"publisher","DOI":"10.1155\/2017\/6096134"},{"key":"e_1_3_4_23_2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2016.00012"},{"key":"e_1_3_4_24_2","doi-asserted-by":"publisher","DOI":"10.1038\/nm.1972"},{"key":"e_1_3_4_25_2","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a007179"},{"key":"e_1_3_4_26_2","doi-asserted-by":"publisher","DOI":"10.1038\/srep23513"},{"key":"e_1_3_4_27_2","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.5473-10.2011"},{"key":"e_1_3_4_28_2","first-page":"w12618","article-title":"Modeling HIV infection and therapies in humanized mice","volume":"142","author":"Nischan M","year":"2012","unstructured":"Nischan M, , Gers-Huber G, , Audige A, et al.: Modeling HIV infection and therapies in humanized mice. Swiss Med Wkly, 2012; 142:w12618.","journal-title":"Swiss Med Wkly"},{"key":"e_1_3_4_29_2","first-page":"786","article-title":"Humanized mice for immune system investigation: Progress, promise and challenges","volume":"12","author":"Shultz LD","year":"2012","unstructured":"Shultz LD, , Brehm MA, , Garcia-Martinez JV, et al.: Humanized mice for immune system investigation: Progress, promise and challenges. Nat Rev, 2012; 12:786\u2013798.","journal-title":"Nat Rev"},{"key":"e_1_3_4_30_2","doi-asserted-by":"publisher","DOI":"10.1089\/aid.2015.0020"},{"key":"e_1_3_4_31_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.02118-17"},{"key":"e_1_3_4_32_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.virol.2009.10.034"},{"key":"e_1_3_4_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2014.07.043"},{"key":"e_1_3_4_34_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12977-017-0344-7"},{"key":"e_1_3_4_35_2","first-page":"360","article-title":"Long-term control of HIV by CCR5 Delta 32\/Delta stem\u2013cell transplantation","volume":"12","author":"Hutter G","year":"2009","unstructured":"Hutter G, , Nowak D, , Mossner M, et al.: Long-term control of HIV by CCR5 Delta 32\/Delta stem\u2013cell transplantation. N Engl J Med, 2009; 12:360.","journal-title":"N Engl J Med"},{"key":"e_1_3_4_36_2","first-page":"24","article-title":"Synergistic inhibition of R5 HIV-1 by the fusion protein (FLSC) IgG1 Fc and Maraviroc in primary cells: Implications for prevention and treatment","volume":"1","author":"Latinovic OS","year":"2016","unstructured":"Latinovic OS, , Zhang J, , Tagaya Y, et al.: Synergistic inhibition of R5 HIV-1 by the fusion protein (FLSC) IgG1 Fc and Maraviroc in primary cells: Implications for prevention and treatment. Curr HIV Res, 2016; 1:24\u201336.","journal-title":"Curr HIV Res"},{"key":"e_1_3_4_37_2","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e3283471edb"},{"key":"e_1_3_4_38_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejps.2018.02.026"},{"key":"e_1_3_4_39_2","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e328353f3f1"},{"key":"e_1_3_4_40_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.49.11.4721-4732.2005"},{"key":"e_1_3_4_41_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2017.09.080"},{"key":"e_1_3_4_42_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11904-014-0246-4"},{"key":"e_1_3_4_43_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.01049-07"},{"key":"e_1_3_4_44_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13293-014-0015-5"},{"key":"e_1_3_4_45_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.41.10.4531-4536.2003"},{"key":"e_1_3_4_46_2","first-page":"345","article-title":"Human peripheral blood mononuclear cell substrate for propagating wild type HIV-1","volume":"106","author":"Vyas GN","year":"2001","unstructured":"Vyas GN: Human peripheral blood mononuclear cell substrate for propagating wild type HIV-1. Dev Biol (Basel), 2001; 106:345\u2013456.","journal-title":"Dev Biol (Basel)"},{"key":"e_1_3_4_47_2","doi-asserted-by":"publisher","DOI":"10.2174\/0929867321666140826114135"},{"key":"e_1_3_4_48_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.06120-11"},{"key":"e_1_3_4_49_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0038853"},{"key":"e_1_3_4_50_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2055-6640(20)30684-1"},{"key":"e_1_3_4_51_2","first-page":"e1368","article-title":"Evaluation of the innate immune modulator acitretin as a strategy to clear the HIV reservoir","volume":"61","author":"Garcia-Vadal E","year":"2017","unstructured":"Garcia-Vadal E, , Castelvi M, , Pujantell M, et al.: Evaluation of the innate immune modulator acitretin as a strategy to clear the HIV reservoir. Antimicrob Agents Chemother, 2017; 61:e1368-11.","journal-title":"Antimicrob Agents Chemother"},{"key":"e_1_3_4_52_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.coviro.2016.03.004"},{"key":"e_1_3_4_53_2","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2018.00462"},{"key":"e_1_3_4_54_2","doi-asserted-by":"publisher","DOI":"10.1002\/jia2.25063"},{"key":"e_1_3_4_55_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-15630-z"},{"key":"e_1_3_4_56_2","doi-asserted-by":"publisher","DOI":"10.1089\/aid.2015.0211"},{"key":"e_1_3_4_57_2","volume-title":"The Body","author":"Tobira Therapeutics Initiates Phase 2b Trial of Cenicriviroc","year":"2011","unstructured":"Tobira Therapeutics Initiates Phase 2b Trial of Cenicriviroc. The Body, 2011."}],"container-title":["AIDS Research and Human Retroviruses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1089\/aid.2018.0305","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/aid.2018.0305","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/aid.2018.0305","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T09:14:41Z","timestamp":1777367681000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/full\/10.1089\/aid.2018.0305"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8]]},"references-count":56,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2019,8]]}},"alternative-id":["10.1089\/aid.2018.0305"],"URL":"https:\/\/doi.org\/10.1089\/aid.2018.0305","relation":{},"ISSN":["0889-2229","1931-8405"],"issn-type":[{"value":"0889-2229","type":"print"},{"value":"1931-8405","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,8]]}}}